A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes

被引：0
|
作者：
de Castro, C. [1 ]
Adams, D. [1 ]
Rizzieri, D. [1 ]
Moore, J. [1 ]
Gockerman, J. [1 ]
Diehl, L. [1 ]
Horwitz, M. [1 ]
Edmonds, E. [1 ]
Warzecho, J. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC 27706 USA
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70210-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S134 / S134
页数：1
相关论文
共 50 条
  • [1] A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
    Wei, Wei
    Zhou, Fan
    Zhang, Yizi
    Guo, Lieping
    Shi, Haotian
    Hou, Jian
    LEUKEMIA RESEARCH, 2012, 36 (06) : 715 - 719
  • [2] Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study
    Vey, N
    Bosly, A
    Guerci, A
    Feremans, W
    Dombret, H
    Dreyfus, F
    Bowen, D
    Burnett, A
    Dennis, M
    Ribrag, V
    Casadevall, N
    Legros, L
    Fenaux, P
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2465 - 2471
  • [3] Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
    Schiller, Gary J.
    Slack, James
    Hainsworth, John D.
    Mason, James
    Saleh, Mansoor
    Rizzieri, David
    Douer, Dan
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2456 - 2464
  • [4] Arsenic trioxide for the treatment of myelodysplastic syndromes
    Vey, N
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (03) : 613 - 621
  • [5] Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study
    Welch, John S.
    Klco, Jeffery M.
    Gao, Feng
    Procknow, Elizabeth
    Uy, Geoffery L.
    Stockerl-Goldstein, Keith E.
    Abboud, Camille N.
    Westervelt, Peter
    DiPersio, John F.
    Hassan, Anjum
    Cashen, Amanda F.
    Vij, Ravi
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (09) : 796 - 800
  • [6] A Phase 2 Study of Combination Therapy With Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    Erba, Harry P.
    Afable, Manuel
    Englehaupt, Ricki
    Sobecks, Ronald
    Advani, Anjali
    Seel, Sherry
    Chan, Josephine
    Kalaycio, Matt E.
    CANCER, 2011, 117 (06) : 1253 - 1261
  • [7] Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes
    List, A
    Beran, M
    DiPersio, J
    Slack, J
    Vey, N
    Rosenfeld, CS
    Greenberg, P
    LEUKEMIA, 2003, 17 (08) : 1499 - 1507
  • [8] Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes
    A List
    M Beran
    J DiPersio
    J Slack
    N Vey
    C S Rosenfeld
    P Greenberg
    Leukemia, 2003, 17 : 1499 - 1507
  • [9] Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes?
    Stone, Richard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2414 - 2416
  • [10] New data with arsenic trioxide in leukemias and myelodysplastic syndromes
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 8 : S7 - S12
12345